Clinical Trials Logo

Stage IV Breast Cancer clinical trials

View clinical trials related to Stage IV Breast Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06439693 Not yet recruiting - Breast Cancer Clinical Trials

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Start date: November 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1), followed by Trastuzumab plus Pertuzumab plus Tucatinib) in HER2+ Breast Cancer. The study will help investigators understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for participants. The names of the study drugs involved in this study are: - Paclitaxel (a type of anti-microtubule agent) - Docetaxel (a type of anti-microtubule agent) - Nab-Paclitaxel (a type of anti-microtubule agent) - Trastuzumab (a type of IgG1 kappa monoclonal antibody) - Pertuzumab (a type of monoclonal antibody) - Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate) - Tucatinib (Tyrosine Kinase HER2 Inhibitor) - Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate)

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.